ZYDUS ANIMAL HEALTH LTD
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 24%
Last few days of movement of the Nifty and Sense will make a number of people forget about what happened in March this year. The fact is that when valuations are high and they are even if takes into account the Q4 numbers. The probability of volatility hitting the street is always high. So, it would be better to stay ready for volatility both for domestic and global reasons. At this point of time, one cannot rule out sudden profit booking which can bring more damage to stock prices in the mid-cap segment. In such times, if one is taking fresh exposure to equity, ensure that there is some level of quality as far as the business and fundamentals are concerned. These selected stocks depict a strong upward trajectory in their overall average score which is based on five key pillars i.e. earnings, fundamentals, relative valuation, risk and price momentum. This implies that there has been a significant improvement in their market outlook in the given time.
Multiples PE-backed Zenex acquires Dabur promoter Pradeep Burman's Ayurvet
Ayurvet, founded as a subsidiary of Dabur India in 1992 and later spun off as an independent entity in 2002, is a leading provider of ayurvedic and herbal medicines, feed supplements and topical treatments for farm and companion animals.
Another Jhunjhunwala long bet blooms with Concord Biotech offer
The ace investor often called India's Warren Buffet, first invested in Concord in 2004 and later helped the company's founder in buying back the company from pharma major Mylan in 2009.
Stocks in news: TCS, HDFC Life, Shree Cement, Aurobindo Pharma, Bank of Maharashtra
The European Medicines Agency’s (EMA) Committee has accepted Aurobindo Pharma subsidiary CuraTeQ Biologics' request to withdraw the applications for marketing authorization of ZEFYLTI (a filgrastim biosimilar) and DYRUPEG (a pegfilgrastim biosimilar).
Zydus picks 6.5% in Mylab from Adar Poonawala co for ₹106 Cr
Mylab came into limelight during Covid pandemic when it developed and launched indigenous RT-PCR test kits and platform for diagnosing Covid.
Stocks in news: SBI Life, Indian Overseas Bank, IOC, IDFC First Bank
USFDA has conducted an inspection at Zydus’ animal health drug manufacturing facility at SEZ, Ahmedabad. The inspection concluded with nil observations.
- Go To Page 1
ZyCov-D vaccine will hit markets soon: Union health minister
The company's indigenously developed needle-free three-dose COVID-19 vaccine ZyCoV-D was granted emergency use authorisation (EUA) by the drug regulator on Friday, making it the first vaccine to be administered to beneficiaries in the age group of 12-18 years in the country.
Cadila arm completes sale of animal health business for Rs 2,921 crore
In May this year, Zydus Animal Health and Investment has entered into definitive pacts for sale of its animal healthcare established markets undertaking to Multiples Alternate Asset Management-led consortium for Rs 2,921 crore.
The 2-billion Vaccine Question: How realistic are estimates and what's the current status?
The Centre’s plan for 2 billion doses of Covid-19 vaccines by year-end depends on a massive ramp-up of production as well as flawless trials, approval and manufacturing of five new vaccines. How realistic are the estimates? In what stages are the new vaccines now?
Multiples, CPPIB and Jhunjhunwala’s RARE to buy Cadila’s Animal Health biz for Rs 2921 crores
The consortium, through an SPV controlled by them, has signed a definitive agreement to acquire Animal Healthcare Established Markets Undertaking focused on India and certain other countries, the company said in a statement.
Cadila Healthcare Q3 results: Net profit up 41% to Rs 527 crore
The company had posted a net profit of Rs 373.9 crore for the corresponding period of the previous fiscal, Cadila Healthcare said in a filing to BSE.
PE funds eye Zydus Cadila's animal health business
The proposed deal is expected to value Zydus Animal Health and Investments (Zydus AHL) at Rs 2,500 crore, or about $350 million, they said. Non-binding bids will be submitted by end of February and the due diligence will start after that, one of the sources told ET.
Seven Indian pharmaceutical companies race to develop vaccine for deadly coronavirus
Bharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms working on the coronavirus vaccines in India. Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a vaccine within months.
Scientists strike note of caution as 'Made in India' vaccine programme gains momentum
India's premier medical body ICMR has said 12 clinical trial sites for the indigenous Covaxin, being developed in collaboration with the Hyderabad-based Bharat Biotech and the National Institute of Virology (NIV), have been identified.
COVID-19 vaccine by Ahmedabad-based Zydus Cadila gets DCGI nod for human clinical trials
The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI, in which the vaccine candidate was found to be successful with respect to safety and immunogenicity, sources said.
COVID-19 vaccine development at early stage in India; breakthrough unlikely within a year: Experts
Referring to a vaccine to fight the virus, a PMO statement had said that it is the most pressing need and Indian academia, start-ups and industry have come together in cutting-edge vaccine design and development.
Market Movers: RIL, YES Bank, RBL jump; 18 shares send out ‘buy’ signals
RBL Bank and YES Bank jumped 9 per cent and 36 per cent, respectively, after positive commentaries from their respective managements.
Centre likely to cap veterinary drug prices
Centre is mulling to cap the prices of a new catalogue of veterinary drugs and vaccines in a bid to boost the Prime Minister's new initiative to control livestock diseases. The move could impact companies in the animal healthcare business in India.
Zydus Cadila receives DCGI nod to market rabies drug in India
Zydus said it currently also manufactures and markets the rabies vaccine — VaxiRab.
Top stocks in focus on Thursday, 6 July 2017
Here is a list of top stocks that are likely to be in focus today.
Sanofi, Boehringer Ingelheim seek CCI nod for $25-billion global asset swap deal
The commission will review if the two companies swapping their businesses will cause any adverse impact on the local competition.
Zydus Cadila to acquire select animal health brands from Zoetis
Zydus operates its veterinary business through Zydus Animal Health. The company did not disclose the financial details of the deal.
Cadila Healthcare to delist from Ahmedabad Stock Exchange, will remain listed on BSE and NSE
The company's board, which met today, decided to delist equity shares of the company from ASE, Cadila Healthcare said in a filing to the BSE.
Cadila Healthcare recalls 15,144 bottles of hypertension drug in US
As per information available on the USFDA website, Zydus Pharmaceuticals USA Inc, the US-based arm of the company, is recalling the drug due to "discoloration".
Cadila Healthcare recalls blood pressure drug in the US
The recall of the 5,400 bottles has been voluntarily initiated by the company through its US based arm Zydus Pharmaceuticals USA Inc.
Why Cadila Healthcare is likely to be an underperformer in the pharma sector
Due to the current challenges related to the new drug pricing policy, the company is likely to face slowdown in the domestic market.
Cadila not an attractive bet due to drug pricing policy
In the March quarter, a strong performance in the domestic formulations business, and the exports business in Europe and emerging markets proved to be major growth drivers.
Zydus Cadila Group to merge its three subsidiaries with its listed entity Cadila Healthcare Ltd
In 2000, Zydus Cadila had created a strategic alliance with Ambalal Sarabhai Enterprises to integrate the animal healthcare business of both the group to create 'Sarabhai Zydus Animal Health Ltd'.
Cadila Healthcare to merge certain subsidiaries with itself
Drug maker Cadila Healthcare today said its board has approved the merger of various wholly-owned subsidiaries, including Zydus Animal Health Ltd with itself.
Load More
